Roche Receives FDA Approval for Tecentriq in PD-L1-Positive Triple-Negative Breast Cancer

Roche today announced that the FDA has approved Tecentriq (atezolizumab) in combination with nab-paclitaxel for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. In the Phase 3 IMpassion130 trial, Tecentriq plus nab-paclitaxel demonstrated a statistically significant improvement in progression-free survival in the PD-L1-positive population. The median PFS was 7.5 months for Tecentriq plus nab-paclitaxel versus 5.0 months for placebo plus nab-paclitaxel. This approval provides patients with PD-L1-positive TNBC a new first-line treatment option.